On July 31, 2008, AtheroGenics, Inc. issued a press release to report the company's top-line results for the ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type-2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits.
The following exhibit is furnished as part of this current report on Form 8-K.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.